A
Andreas Jung
Researcher at Ludwig Maximilian University of Munich
Publications - 297
Citations - 25322
Andreas Jung is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Colorectal cancer & KRAS. The author has an hindex of 63, co-authored 277 publications receiving 22884 citations. Previous affiliations of Andreas Jung include University of Erlangen-Nuremberg & Osaka University.
Papers
More filters
Journal ArticleDOI
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Hiroki Kato,Osamu Takeuchi,Shintaro Sato,Mitsutoshi Yoneyama,Masahiro Yamamoto,Kosuke Matsui,Satoshi Uematsu,Andreas Jung,Taro Kawai,Ken Ishii,Osamu Yamaguchi,Kinya Otsu,Tohru Tsujimura,Chang-Sung Koh,Caetano Reis e Sousa,Yoshiharu Matsuura,Takashi Fujita,Shizuo Akira +17 more
TL;DR: It is found that RIG-I is essential for the production of interferons in response to RNA viruses including paramyxoviruses, influenza virus and Japanese encephalitis virus, whereas MDA5 is critical for picornavirus detection.
Journal ArticleDOI
5'-Triphosphate RNA Is the Ligand for RIG-I
Veit Hornung,Jana M. Ellegast,Sarah Kim,Krzysztof Brzózka,Andreas Jung,Hiroki Kato,Hendrik Poeck,Shizuo Akira,Karl-Klaus Conzelmann,Martin Schlee,Stefan Endres,Gunther Hartmann +11 more
TL;DR: It is demonstrated that the 5′-triphosphate end of RNA generated by viral polymerases is responsible for retinoic acid–inducible protein I (RIG-I)–mediated detection of RNA molecules in viruses known to be detected by MDA-5 such as the picornaviruses.
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Migrating cancer stem cells — an integrated concept of malignant tumour progression
TL;DR: An extended, integrated model that is consistent with all aspects of human tumour progression is suggested — the 'migrating cancer stem (MCS)-cell' concept.
Journal ArticleDOI
Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment
Thomas Brabletz,Andreas Jung,Simone Reu,Marc Porzner,Falk Hlubek,Leoni A. Kunz-Schughart,Ruth Knuechel,Thomas Kirchner +7 more
TL;DR: It is postulate that an important driving force for progression of well-differentiated colorectal carcinomas is the specific environment, initiating two transient phenotypic transition processes by modulating intracellular β-catenin distribution in tumor cells.